WO2000072824A1 - Microliposomes et leur procede de production - Google Patents
Microliposomes et leur procede de production Download PDFInfo
- Publication number
- WO2000072824A1 WO2000072824A1 PCT/JP2000/003472 JP0003472W WO0072824A1 WO 2000072824 A1 WO2000072824 A1 WO 2000072824A1 JP 0003472 W JP0003472 W JP 0003472W WO 0072824 A1 WO0072824 A1 WO 0072824A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ribosome
- mass
- parts
- lipid
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
Definitions
- the present invention relates to a ribosome produced using a saccharide and a method for producing the ribosome. More specifically, the present invention relates to a minute ribosome produced using a high concentration of saccharide, and a method for producing the same. Background art
- a ribosome is a closed packet of lipids, and is used to intentionally direct a drug encapsulated inside the packet to a specific site in the body, and to ensure the stability and sustainability of release of the drug. ing.
- the particle size is an important factor in pharmacokinetics, and is deeply related to, for example, disappearance from the blood circulatory system, distribution to tissues, absorption by organs, and transfer between tissues. In order to perform these operations smoothly, fine particles are preferable. Also, by reducing the particle size, the filtration required for injections and sterilization by filtration can be performed. Thus, the particle size is an important factor in injectable preparations.
- Conventional methods for producing ribosomes often include a first step of hydrating and swelling a phospholipid in an aqueous dispersion medium and a second step of miniaturizing to obtain a desired particle size.
- Various ideas have been devised in the step.
- the solvent is distilled off from a solution in which the lipid is dissolved in a volatile organic solvent, a thin film made of lipid or the like is formed on the inner wall of the container, an aqueous dispersion medium is added and stirred, and the lipid thin film is formed.
- a method of hydrating and swelling Although this method is relatively simple, the ribosome after hydration and swelling is a multilayer packet, and its particle size is relatively large, about several to several hundred microns. Therefore, when it is necessary to reduce the particle size to a small particle size of an injection or the like, a miniaturization step is required.
- Methods for the second step of miniaturization of liposomes and uniformization of particle size distribution include, for example, extrusion using a polycarbonate filter, high-pressure emulsification, and ultrasonic irradiation (see Ribosome (Nan-Edo, 1988)). . If the hydrated ribosomes before micronization have a large particle size, the ribosome dispersion may be repeatedly passed through the same size of polycarbonate filter (see Patent No. 2537186 (W ⁇ )). 860 238, EP 185 57 56) Refer to the specification), emulsification at high pressure and extension of ultrasonic irradiation time are required, and the production time and the size of production equipment become problematic.
- surfactant removal method for example, well-known methods include (1) surfactant removal method and organic solvent injection method (see Ribosome (Nankodo, 1988), Manual for liposome experiments in life sciences (Springer Fairlark Tokyo, 1992)).
- the surfactant removal method is known as a method for obtaining minute ribosomes by solubilizing lipid with a surfactant and then removing the surfactant.
- an apparatus for removing the surfactant is required, and the processing time becomes a problem.
- the organic solvent injection method involves dissolving lipids in a water-soluble organic solvent such as ethanol and injecting the solution into an aqueous dispersion medium.
- a water-soluble organic solvent such as ethanol
- This method is easy to hydrate, and is a method for producing minute liposomes.
- the particle size of the liposome obtained by this method greatly depends on the concentration of the lipid solution, and a finer ribosome can be obtained by making the lipid solution more dilute. However, diluting the lipid solution inevitably increases the amount of organic solvent used.
- each method has various problems, and the reduction in the particle size of the liposome after hydration is not sufficient.
- the main purposes of adding these are (1) tonicity when used as an injection, (2) retention of ribosome form during lyophilization, or (3) to use as a core substance when forming lipid thin films. is there.
- Japanese Patent Application Laid-Open No. 9-110828 states that saccharides (lactose, mannitol, etc.) can be added as an auxiliary agent other than the active ingredient.
- saccharides lactose, mannitol, etc.
- Maltose solution is used (Example 4).
- Ribosome technology (edited by Gregory Gregoriadis, LIPOSOME TECHNOLOGY, Vol. I, 2nd Edition, 229-252 (published in 1993)) examined the effects of various sugars on the retention of ribosome shape during freeze-drying. ing.
- Japanese Patent Publication No. 3-69669 discloses that the characteristics of liposome preparations can be improved by freeze-drying using a saccharide as an excipient, and the saccharide concentration during production is 1 to 10%. %a.
- Japanese Patent Publication No. 5-51338 (EP 1 19020) The specification describes a method of coating a water-soluble granular carrier substance with a ribosome thin film, and the carrier substance includes sorbitol, mannitol, xylitol, naturally occurring amino acids, ! Sucrose, dextrose and sucrose. It is stated that an isotonic aqueous solution having a concentration of about 1 to 10 W / V, preferably about 3 to 7% WZV should be formed.
- saccharides are conventionally added when producing ribosomes, but none of them are added for the purpose of producing minute ribosomes, and their concentrations are isotonic, about 10%. It is not used at high concentrations as in the present invention. Disclosure of the invention
- An object of the present invention is to provide a method for efficiently producing fine ribosomes without using an organic solvent as much as possible and without using severe physical treatment means, and a fine ribosome obtained by the production method. It is in.
- the present inventors have conducted intensive studies to solve the above problems, and as a result, in the liposome production process, small liposomes can be easily and efficiently used by using a high concentration of saccharides which are not employed in the conventional technology.
- the present inventors have found that the present invention can be manufactured with ease, and completed the present invention.
- the present invention provides the following minute ribosome and a method for producing the same.
- a method for producing fine liposomes which comprises injecting and mixing a ribosomal raw material containing lipids into a high-concentration aqueous sugar solution or sugar slurry.
- the ribosome raw material containing lipids is injected and mixed into a high-concentration aqueous solution or slurry of sugar to obtain ribosomes with a particle diameter of less than 400 nm 1
- the present invention relates to a fine ribosome obtained by injecting and mixing a ribosome raw material containing lipids into a high-concentration aqueous saccharide solution or saccharide slurry in which saccharide and water are mixed by heating or stirring, and a method for producing the ribosome.
- small ribosomes can be easily and efficiently obtained with a small amount of organic solvent used and without employing severe physical treatment means.
- saccharides are used in high concentrations. Specifically, a mixture of 10 to 30 parts by mass of water and 1 to 30 parts by mass of water is used. It is preferably used in a ratio of 2 to 15 parts by mass of water to 10 parts by mass of saccharide, and more preferably in a ratio of 3 to 10 parts by mass of water to 10 parts by mass of saccharide.
- the saccharide is used in the form of a solution or a slurry.
- saccharide used in the present invention examples include monosaccharides such as glucose, fructose, and galactose; disaccharides such as maltose, lactose, sucrose, and trehalose; and sugar alcohols such as xylitol, mannitol, and erythritol. Yes, both are preferred.
- the saccharides may be used alone or in combination of two or more. More preferably, glucose, maltose, lactose, sucrose, trehalose, xylitol or a combination thereof is used. Particularly preferably, maltose is used.
- the ratio of sugar to lipid is not limited.
- the lipid is used in a ratio of not more than 5 parts by mass of the lipid in the ribosome raw material containing the lipid to 10 parts by mass of the saccharide. More preferably, the ribosome raw material is used in such an amount that the lipid in the ribosome raw material is not more than 1 part by mass, particularly preferably 0.0001 to 0.5 part by mass, based on 10 parts by mass of the sugar.
- Examples of the lipid used in the present invention include a phospholipid and a glycolipid.
- a phospholipid and a glycolipid for example, egg yolk lecithin, soy lecithin, phosphatidylcholine (dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distear mouth phosphatidylcholine, etc.), lysophosphatidylcholine, phosphatidyl glycerol (dimyristoyl phosphatidylglycerol phosphatidylglyceryl phosphatidylglyceryl phosphatidylglycerol Phosphatidylserine, phosphatidylethanolamine, sphingomyelin, dicetyl phosphate, phosphatidic acid or a mixture thereof, all of which are preferred.
- yolk lecithin phosphatidylcholine (such as dimyristoyl phosphatidylcholine, dipalmitylphosphatidylcholine, distearoylphosphatidylcholine, etc.), Phatidyl glycerol (dimyristoyl phosphatidyl glycerol, dipalmitoyl phosphatidyl glycerol, distearoyl phosphatidyl glycerol, etc.), or a mixture thereof.
- phosphatidylcholine such as dimyristoyl phosphatidylcholine, dipalmitylphosphatidylcholine, distearoylphosphatidylcholine, etc.
- Phatidyl glycerol diimyristoyl phosphatidyl glycerol, dipalmitoyl phosphatidyl glycerol, distearoyl phosphatidyl glycerol, etc
- a membrane stabilizing substance for example, cholesterol or the like can be added.
- an antioxidant for example, heart tocopherol or the like can be added.
- the lipid used in the present invention is added in the form of a solution, preferably a concentrated solution, or a lipid thin film or powder obtained by removing the solvent from the lipid solution.
- a solvent for the lipid solution a water-soluble organic solvent is used.
- there are lower alcohols having up to 4 carbon atoms such as methanol and ethanol, acetone and acetonitrile, all of which are preferred. More preferably, ethanol is used.
- a minute liposome can be produced with a small amount of an organic solvent used.
- the organic solvent is used in an amount of 1 to 100 parts by mass with respect to 10 parts by mass of the lipid. It is more preferably used at a ratio of 1 to 50 parts by mass.
- the ribosome of the present invention can be made into a lyophilized preparation. At that time, some organic solvent used in the production of the ribosome remains. However, in the present invention, since a small amount of organic solvent can be used to produce a small ribosome, the amount of remaining organic solvent can be small. For example, when ribosomes are freeze-dried using 1 to 100 parts by mass of an organic solvent with respect to 10 parts by mass of a lipid, the remaining organic solvent is 0.5 to 50 parts by mass, more preferably, It becomes a small amount of about 0.5 to 30 parts by mass. In the present invention, the physiologically active substance held by the ribosome is not particularly limited.
- a water-soluble physiologically active substance is previously added to a sugar aqueous solution or sugar slurry, and a lipid-containing liposome raw material is injected therein.
- the hydrophobic bioactive substance is It is dissolved in a medium, mixed with ribosome raw materials containing lipids, and injected into an aqueous sugar solution or sugar slurry.
- stirring can be performed if necessary.
- the stirring may be carried out by ordinary stirring power or stirring using an emulsifying / dispersing device such as a homogenizer.
- an emulsifying / dispersing device such as a homogenizer.
- the particle size can be rapidly reduced by stirring using a device that promotes emulsification and dispersion.
- minute ribosomes can be obtained without using severe physical treatment. For example, it is possible to obtain small ribosomes with a particle size (measured by dynamic light scattering method) of about 400 nm or less, and easily obtain ribosomes with a particle size of 300 nm or less. Can be. Further, the obtained fine liposome can be diluted if necessary.
- the particle size of the ribosome produced according to the present invention is small enough for practical use, further physical treatment is performed to further reduce the particle size or make the particle size distribution more uniform, for example, A treatment such as extrusion, high-pressure emulsification, or ultrasonic irradiation using a polycarbonate filter may be performed.
- a treatment such as extrusion, high-pressure emulsification, or ultrasonic irradiation using a polycarbonate filter may be performed.
- the ribosome containing the physiologically active substance obtained in the present invention is formulated into an injection for parenteral administration, for example, a ribosome injection solution or a solid injection dissolved or suspended in a solvent before use.
- This injection may contain stabilizers, suspending agents, emulsifiers, soothing agents, buffers, preservatives and the like. They are prepared by sterilization or aseptic processing in the final step.
- a sterile solid preparation for example, a lyophilized product can be produced, and then sterilized or dissolved in sterile distilled water for injection or other solvents before use.
- compositions for parenteral administration include, for example, liquid preparations for external use, ointments, liniments, inhalants, sprays, suppositories, and pessaries for vaginal administration.
- Example 2 Water (1 L) was added to maltose (1 kg) and dissolved by heating. A lecithin solution consisting of egg yolk lecithin (0.5 g), ethanol (1.0 g) and a fat-soluble drug (PGE 1 ⁇ (dodecanoyloxy) ethyl ester; 0.05 g) was injected into a 50% aqueous maltose solution cooled to room temperature. The solution was stirred at 8,000 rpm for 30 minutes to obtain the ribosome of the present invention. The ribosome was diluted with water to a total volume of 10 L, and the average particle size was estimated by dynamic light scattering. As a result, the ribosome particle size was 190 nm. Example 2
- Example 4 Water (2.5L) was added to maltose (2.5kg) and dissolved by heating.
- a lecithin solution consisting of egg yolk lecithin (12 g), ethanol (20 g), and a fat-soluble drug (PGE1, (dodecanolyloxy) ethyl ester; 1 g) was injected into a 50% maltose aqueous solution cooled to room temperature. .
- the solution was stirred at 8,000 rpm for 30 minutes to obtain a ribosome of the present invention. 25 total ribosomes in water After diluting to L and estimating the average particle size by dynamic light scattering, the ribosome particle size was 210 nm.
- Example 4 Example 4
- the ribosome was diluted with water to a total volume of 10 L, and the average particle size was estimated by dynamic light scattering. As a result, the ribosome particle size was 200 nm.
- a solution consisting of dimyristoyl phosphatidylcholine (0.1 lg) and ethanol (0.2 g) was injected into a malt slurry obtained by adding water (8 ml) to maltose (20 g). The slurry was stirred at 100 revolutions per minute for 60 minutes to obtain the ribosome of the present invention.
- the ribosome was diluted with water to a total volume of 20 Om1, and the average particle size was estimated by dynamic light scattering. As a result, the ribosome particle size was 130 nm.
- Maltose slurry (maltose (20 g) plus water (8 ml)) was mixed with dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol and cholesterol mixture (65: 5: 30) (0.2 g) and ethanol (0.3 g). Solution was injected. The slurry was stirred at 100 rpm for 60 minutes to obtain the ribosome of the present invention. The ribosome was diluted with water to a total volume of 20 Oml, and the average particle size was estimated by dynamic light scattering. As a result, the liposome particle size was 220 nm. Comparative example A lecithin solution consisting of egg yolk lecithin (0.3 g) and ethanol (3.
- a lecithin solution consisting of egg yolk lecithin (0.6 g) and ethanol (0.8 g) was injected into 50% aqueous solutions (20 ml) of various sugars. The solution was stirred at 100 revolutions per minute for 24 hours to obtain the ribosome of the present invention. This liposome was diluted with water to a total volume of 10 Om1. The turbidity was calculated by measuring the absorbance of the diluted solution at a wavelength of 400 nm. The results are shown in Table 1.
- Turbidity is a value used as an index of particle size. The smaller the turbidity, the smaller the particle size. (Edited by Gregory Gregoriadis, LIPOSOME TECHNOLOGY, Vol. I, 2nd Edition, 568-571 (issued in 1993)).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020017015314A KR20020011993A (ko) | 1999-06-01 | 2000-05-30 | 미소한 리포좀 및 그 제조 방법 |
AU49510/00A AU4951000A (en) | 1999-06-01 | 2000-05-30 | Microliposomes and process for producing the same |
EP00931610A EP1181928A1 (en) | 1999-06-01 | 2000-05-30 | Microliposomes and process for producing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/153579 | 1999-06-01 | ||
JP15357999 | 1999-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000072824A1 true WO2000072824A1 (fr) | 2000-12-07 |
Family
ID=15565586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/003472 WO2000072824A1 (fr) | 1999-06-01 | 2000-05-30 | Microliposomes et leur procede de production |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1181928A1 (ja) |
KR (1) | KR20020011993A (ja) |
AU (1) | AU4951000A (ja) |
WO (1) | WO2000072824A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013255912A (ja) * | 2012-05-15 | 2013-12-26 | Chiba Univ | リポソームおよびその作製方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS607933A (ja) * | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造法 |
JPH03123637A (ja) * | 1989-10-05 | 1991-05-27 | Kao Corp | リポソーム形成剤及びリポソーム組成物 |
JPH06239734A (ja) * | 1993-02-18 | 1994-08-30 | Kanebo Ltd | リポソームの調製法及びリポソーム製剤 |
-
2000
- 2000-05-30 AU AU49510/00A patent/AU4951000A/en not_active Abandoned
- 2000-05-30 KR KR1020017015314A patent/KR20020011993A/ko not_active Application Discontinuation
- 2000-05-30 EP EP00931610A patent/EP1181928A1/en not_active Withdrawn
- 2000-05-30 WO PCT/JP2000/003472 patent/WO2000072824A1/ja not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS607933A (ja) * | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造法 |
JPH03123637A (ja) * | 1989-10-05 | 1991-05-27 | Kao Corp | リポソーム形成剤及びリポソーム組成物 |
JPH06239734A (ja) * | 1993-02-18 | 1994-08-30 | Kanebo Ltd | リポソームの調製法及びリポソーム製剤 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013255912A (ja) * | 2012-05-15 | 2013-12-26 | Chiba Univ | リポソームおよびその作製方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20020011993A (ko) | 2002-02-09 |
AU4951000A (en) | 2000-12-18 |
EP1181928A1 (en) | 2002-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maja et al. | Sustainable technologies for liposome preparation | |
DE69432358T2 (de) | Gashaltige mikrosphären zur topischen und subkutanen anwendung | |
Guillot et al. | Skin drug delivery using lipid vesicles: A starting guideline for their development | |
Watwe et al. | Manufacture of liposomes: a review | |
US10322073B2 (en) | Apparatus and method for preparing cosmeceutical ingredients containing epi-dermal delivery mechanisms | |
JP2010508368A (ja) | シングルパスプロセスによるリポソームの製造 | |
EP2368627A1 (en) | Method for producing liposome and method for dissolving cholesterol | |
WO1995024201A1 (fr) | Preparation de liposomes | |
JPH11507369A (ja) | プレリポソーム凍結乾燥体から得られるサブミクロンリポソーム懸濁液 | |
KR101102834B1 (ko) | 신규한 리포좀 제조 방법 및 장치 | |
Mansour et al. | Lipid nanoparticulate drug delivery and nanomedicine | |
CH684308A5 (de) | Liposomen enthaltend ein Allylamin. | |
JPH05255070A (ja) | リポソーム製剤およびその製造法 | |
US20080193509A1 (en) | Liposome Preparation Containing Slightly Water-Soluble Camptothecin | |
JP7062639B2 (ja) | 弱酸性の活性作用物質を含有しているリポソーム組成物、リポソーム組成物を調製するための方法およびキット並びに送達用ビヒクル | |
Elhissi et al. | Some approaches to large-scale manufacturing of liposomes | |
CA2279259A1 (en) | Pain reducing parenteral liposome formulation | |
JP2009132629A (ja) | リポソーム製剤の製造方法 | |
WO2000072824A1 (fr) | Microliposomes et leur procede de production | |
JP3249583B2 (ja) | リポソーム製剤 | |
WO2002038128A1 (fr) | Procede de preparation d'une dispersion de microsome | |
JP3329554B2 (ja) | 乾燥小胞体 | |
Verma et al. | Liposomes as carrier systems | |
CN101411687A (zh) | 一种新的脂质体制备方法 | |
Djekic | Liposomes: Properties and therapeutic applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 620936 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017015314 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09980019 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000931610 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017015314 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000931610 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000931610 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017015314 Country of ref document: KR |